

# Executive Summary

## Barricade Therapeutics, Corp.

Based in Dallas-Fort Worth, TX

**Management Team:** Extensive drug development and company-building experience. Over 50 years combined experience in the pharmaceutical industry. Led multiple first-in-human programs in U.S., Canada, and Europe.

- **Neil Thapar, PharmD, RPh**  
Co-Founder, President, CEO & CSO
- **John Walling, PhD**  
Co-Founder, Chief Operating Officer, SVP CMC

### Scientific Advisors:

- **Jef De Brabander, PhD**  
Synthetic Chemist, The Univ. of Texas Southwestern Medical Center (UTSW)
- **Deepak Nijhawan, MD, PhD**  
Clinical Oncologist, UTSW
- **Jerry Shay, PhD**  
Cell Biologist, UTSW
- **Sunil Sharma, MD, FACP., MBA**  
Clinical Oncologist, Physician-in-Chief, Deputy Director, Tgen Clinical Sciences

**Board of Directors:** Experienced entrepreneurs responsible for Multi-Billion \$ exits

- **Carlos Guillem, MBA, PhD**  
President Western Son Distillery, Co-founder CarGin Enterprises LLC, Biotech investor, \$100MM+ capital raises for Pharma Co's, Board member Renibus Therapeutics
- **Darlene Boudreaux, MBA, CPA**  
CFO for Cx Precision Medicine, Inc., Ayuvis Research Inc., Solgro Inc., MedHab LLC and BioNTX
- **Neil Thapar, PharmD, RPh**  
Reata Pharmaceuticals (Acq. by Biogen \$7.3B)

### Funding & Use of Proceeds:

- **2018-19:** Closed \$600K Common Stock Seed Round & \$1.8M Convertible Note
- **2020:** Cancer Prevention Research Institute of Texas (CPRIT) \$3M Product Development Seed Award for CRC Program
- **2022-23:** \$0.5M Convertible Note and \$1.2M tranche of CPRIT funds for GLP Tox studies.
- **2024:** \$14M CPRIT Prod. Dev Award for Phase 1 CRC Trial & current raise \$1M through IND filing (2Q2025) and \$12M Series A for execution of Phase 1 trial.

### Contacts:

**Neil Thapar, CEO**

E-mail: [nthapar@barricadetherapeutics.com](mailto:nthapar@barricadetherapeutics.com)

**Website URL**

[www.BarricadeTherapeutics.com](http://www.BarricadeTherapeutics.com)



## Opportunity | Unmet Medical Needs

Barricade is developing EBP inhibitor drugs to:

- Treat Colorectal Cancer (CRC) patients with the *APC* mutated gene and,
- Remyelinate Nerve Cells in Demyelinating Diseases such as Multiple Sclerosis (MS)

## Problem | Diseases Targeted

**Colorectal Cancer is the 2<sup>nd</sup> most common cancer, affecting 1.8 million people per year**

- Fewer than 1 in 12 patients with advanced CRC survives for five years, and more than 935,000 people die every year from CRC
- ~80% of CRC patients express a mutated *APC* gene. The *APC* gene is the "gate keeper" gene that maintains a healthy colon

**Multiple Sclerosis is the most common demyelinating disease affecting 2.5 million people per year**

- Approved drugs manage symptoms or delay relapse, while none remyelinate nerve cells. TASIN drugs remyelinate nerves, preclinically

## Market & Business Development Opportunity

- **Colorectal Cancer:** est. worldwide market opportunity is \$10 Billion
- **Multiple Sclerosis:** est. market opportunity is \$42 Billion by 2028
- Comparables indicate exit values of \$1B+ with positive clinical CRC data

## Competitive Landscape



**Sumitomo Pharma**

Sumitomo Pharma Oncology

Ongoing Phase 1 Trial in Brain Cancer Patients with DSP-0390 (EBP Inhibitor)

## Competitive Advantage

- Barricade's drug developers & chemists are the world's leading experts at understanding our EBP inhibitor drugs to maximize drug activity (efficacy) while minimizing toxicity.

## Preclinical Proof-of-Concept

**Drug Activity Demonstrated in:**

- The most difficult to treat colorectal cancer patient cell line, DLD1, which harbors *APC<sup>mut</sup>*, *KRAS<sup>mut</sup>*, *TP53<sup>mut</sup>*, and *PIK3CA<sup>mut</sup>* genes
- The Gold Standard *CPC*; *Apc* genetic colorectal cancer mouse model which expresses tumors 90% similar to human colorectal cancers

## Timeline to Testing in Colorectal Cancer (CRC) Patients

- IND-enabling 28-Day GLP toxicology studies have been completed
- Barricade's clinical drug candidate is **BT-1501**
- **Currently planning for FDA pre-IND meeting in 1Q2025**
- **Investigational New Drug (IND) application filing planned 2Q2025**
- **Initiation of Phase 1 trial in *APC<sup>mut</sup>* CRC patients to follow in 2025**

## Intellectual Property

- Issued composition of matter patent (US 10,577,344 B2), priority 2014
- Issued patent (US 10,082,496 B2) covers EBP targeting in cancer
- Planning to file selection invention for BT-1501
- IP nationalized globally, coverage until 2039 (incl. Hatch Waxman ext.)
- Exclusive worldwide license with University of Texas Southwestern